Gathering and analyzing patient experience data in a real-world setting is a key challenge for many

By HEOR Staff Writer

January 18, 2023

Gathering and analyzing patient experience data in a real-world setting is a key challenge for many. To explore this further, ISPOR in Vienna held a second plenary panel featuring experts in the field. What did they discuss?

The panel discussed the importance of rigor in choosing, implementing, and analyzing patient experience data in non-randomized, uncontrolled study designs. Dr. Burgos spoke about the Darwin EU initiative and the importance of stakeholder engagement and capacity building to facilitate patient experience data collection. Professor Devlin discussed the implementation of patient-reported outcome data capture and the PROMs initiatives in the UK, Canada, and New Zealand. Dr. Perfetto spoke about the Core Impact initiative in the US, which standardizes patient experience data collection and the use of core outcome sets.

The panel highlighted the need for further guidance and collaboration with stakeholders to ensure patient experience data is used to inform regulatory decision-making.

Reference url

Recent Posts

pharmaceutical innovation benefits
Pharmaceutical Innovation Benefits Driving Socioeconomic Returns in Europe

By João L. Carapinha

June 23, 2026

Pharmaceutical innovation benefits extend well beyond clinical gains, delivering €5.67 in socioeconomic value for every additional euro spent on newer therapies across 29 European countries from 2014 to 2024. By reducing premature mortality, cutting hospital stays, and increasing workforce partic...
tulisokibart ulcerative colitis
Breakthrough Results with Tulisokibart in Ulcerative Colitis Phase 3 Trial

By João L. Carapinha

June 23, 2026

Tulisokibart ulcerative colitis therapy has achieved a critical milestone, becoming the first anti-TL1A monoclonal antibody to demonstrate clinical remission at week 12 in a Phase 3 trial of patients with moderately to severely active disease. Developed to interrupt immuno-fibrosis — the linked p...
Teplizumab Type 1 Diabetes
Recommendation for Teplizumab Type 1 Diabetes Routine Use

By João L. Carapinha

June 23, 2026

Teplizumab for Type 1 Diabetes now has a clear route to routine NHS use after NICE recommended the therapy for delaying progression from stage 2 to stage 3 disease in people aged 8 and older. The decision, dependent on a confidential commercial discount, offers families more time before insulin d...